DGAP-Ad hoc: Cytori Therapeutics, Inc. deutsch
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;DE;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. deutschAd-hoc-Meldung nach §15 WpHG[weiter]
View ArticleDGAP-Ad hoc: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;EN;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. Ad hoc announcement §15 WpHG[weiter]
View ArticleDGAP-Ad hoc: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;EN;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. Ad hoc announcement §15 WpHG[weiter]
View ArticleDGAP-Ad hoc: Cytori Therapeutics, Inc. deutsch
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;DE;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. deutschAd-hoc-Meldung nach §15 WpHG[weiter]
View ArticleDGAP-Ad hoc: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;EN;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. Ad hoc announcement §15 WpHG[weiter]
View ArticleDGAP-Ad hoc: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;EN;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. Ad hoc announcement §15 WpHG[weiter]
View ArticleDGAP-Ad hoc: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;EN;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. Ad hoc announcement §15 WpHG[weiter]
View ArticleDGAP-Ad hoc: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;EN;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. Ad hoc announcement §15 WpHG[weiter]
View ArticleDGAP-Ad hoc: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;EN;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. Ad hoc announcement §15 WpHG[weiter]
View ArticleDGAP-Ad hoc: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.;US23283K1051;A0ETV6;DRU;;Geregelter Markt;EN;US;XMPA;DGAP-Ad hoc: Cytori Therapeutics, Inc. Ad hoc announcement §15 WpHG[weiter]
View ArticleCytori Therapeutics "buy" - Broadpoint Capital
Rating-Update:New York (aktiencheck.de AG) - Die Analysten von Broadpoint Capital stufen die Aktie von Cytori Therapeutics (ISIN US23283K1051/ WKN A0ETV6) ...[weiter]
View ArticleCytori Therapeutics "market outperform" - Rodman & Renshaw
Rating-Update:New York (aktiencheck.de AG) - Die Analysten von Rodman & Renshaw stufen die Aktie von Cytori Therapeutics (ISIN US23283K1051/ WKN ...[weiter]
View ArticleCytori Therapeutics neues Kursziel - Stanford Financial Group
Rating-Update:Houston (aktiencheck.de AG) - Die Analysten von Stanford Financial Group stufen die Aktie von Cytori Therapeutics (ISIN US23283K1051/ WKN ...[weiter]
View ArticleCytori Therapeutics "market perform" - Rodman & Renshaw
Rating-Update:New York (aktiencheck.de AG) - Die Analysten von Rodman & Renshaw stufen die Aktie von Cytori Therapeutics (ISIN US23283K1051/ WKN ...[weiter]
View ArticleCytori Therapeutics Downgrade - Piper Jaffray
Rating-Update:Minneapolis (aktiencheck.de AG) - Edward A. Tenthoff, Analyst von Piper Jaffray, stuft die Aktie von Cytori Therapeutics (ISIN US23283K1051/ ...[weiter]
View ArticleCytori Therapeutics Downgrade - Rodman & Renshaw
Rating-Update:New York (aktiencheck.de AG) - Ren Benjamin, Analyst von Rodman & Renshaw, stuft die Aktie von Cytori Therapeutics (ISIN US23283K1051/ WKN ...[weiter]
View ArticleCytori Approved to Initiate Pivotal Stem & Regenerative Cell Heart Attack...
SAN DIEGO, CA--(Marketwire - January 20, 2011) - Cytori (NASDAQ:CYTX) receivedapproval from The Netherlands to initiate a pivotal European trial, namedADVANCE, to investigate adipose-derived stem and...
View ArticleCytori Reports Sustained Benefits at 18 Months in Cardiac Cell Therapy Heart...
SAN DIEGO, CA--(Marketwire - June 8, 2011) - Cytori Therapeutics (NASDAQ: CYTX)is reporting 18 month outcomes from its APOLLO trialfor Acute MyocardialInfarction (AMI). The results from the 14 patient,...
View ArticleAktienReport24.com: Cytori Therapeutics ? Das Kursziel beträgt 2,20 Euro
Cytori Therapeutics - Das Kursziel beträgt 2,20 Euro Mittwoch, 04. März 2015Sehr geehrte Investoren,[weiter]
View ArticleCytori Therapeutics to Provide Corporate Update and Investor Presentation...
Cytori Therapeutics to Provide Corporate Update and Investor Presentation Live, at VirtualInvestorConferences.com September 10[weiter]
View ArticleNYSE and Nasdaq Companies to Present Online to Investors on September 10
NYSE and Nasdaq Companies to Present Online to Investors on September 10[weiter]
View ArticleCytori Presentation with Scleroderma Twelve Month Follow Up Data Available...
Cytori Presentation with Scleroderma Twelve Month Follow Up Data Available for Investor Download[weiter]
View ArticleCytori erhält FDA-Zulassung für das Celution System
Cytori Therapeutics, Inc. hat die Zulassung des Center for Devices and Radiological Health (CDRH) der amerikanischen Lebens- und Arzneimittelaufsichtsbeh?rde (FDA) f?r den Celution Zellkonzentrator als...
View ArticleCytori Therapeutics Ersteinschätzung - Piper Jaffray
Rating-Update:Minneapolis (aktiencheck.de AG) - Die Analysten von Piper Jaffray stufen die Aktie von Cytori Therapeutics (ISIN US23283K1051/ WKN A0ETV6) in ...[weiter]
View Article
